ETAP-LAB’s team will attend the upcoming NEUROSCIENCE 2025 from November 15 to 19 in San Diego (USA), with the presentation of two research posters. For the first time, we will also be exhibiting to welcome you and showcase our preclinical services in the neurovascular and neurological fields.
We look forward to seeing you at this world’s largest neuroscience conference, organized by the Society for Neuroscience (SFN), with high-quality programming for scientists from around the world.
📅 When to meet our scientists
ETAP-Lab will unveil two scientific posters on original preclinical results:
Nicolas Violle, CEO and expert in Neuroscience, will present the latest results from our Neuroscience Lab with poster No. PSTR066.10 – “High-throughput brain-on-chip platform for accelerating neurodegenerative drug discovery”.
Session date and time: November 16, 2025, 8:00 AM – 12:00 PM.
Research in partnership with NETRI on the BIO-DIAMOND* program.
Annelise Letourneur, Preclinical Director at STROK@LLIANCE lab, will present the exclusive results of studies conducted for a client, including the successive preclinical stages at STROK@LLIANCE in the development of its stroke drug candidate, with poster No. PSTR443 – “A Translational Multi Model Platform for Preclinical Evaluation of Thrombolytics in Acute Ischemic Stroke”.
Session date and time: Wednesday, November 19, 2025, 1:00 PM – 5:00 PM.
📍 Where to find us
For the first time, we will welcome you at booth #534, with our expert teams ready to advise, as well as Sandra Robelet, our Business Developer.
You will also have the opportunity to meet our new American partner, GEN2X, based in San Diego. We have big surprises in store at our booth, so come and visit us.
🧠 Our models, designed to meet your challenges
We understand the challenges involved in your research to develop your drug candidates.
Do you want to optimize the development of your neurological drugs through translational preclinical studies? Do you need to know how to test the efficacy of your drug candidates? Do you need to reproduce the pathological characteristics of degenerative neurological disorders?
Our teams are committed to providing you with the best advice, quality services, and translational models to facilitate your transition to the next stages, all the way to clinical trials.
SCHEDULE AN APPOINTMENT – WELCOME TO OUR BOOTH #534
More to discover:
Have a look at our range of models and readouts in Neurovascular & Neurology fields.
Register for the congress: Sessions and Events
BIO-DIAMOND program advances here: https://netri.com/biodiamond/
Even more to discover when coming to visit us
We offer efficacy, drug interaction and non-regulatory safety studies in the fields of neurovascular and neurological diseases. Our neuroscience offering relies on a broad portfolio of in vitro to in vivo efficacy models for neurodegenerative diseases (proteinopathies, AD, PD and more), psychopharmacology (motor, mood and learning disorders), as well as ischemic and hemorrhagic strokes. We also offer novel in vitro Brain-on-Chip models.
BIO-DIAMOND program*: a collaborative project with NETRI aiming to accelerate the time-to-market of drug candidates in the discovery and preclinical phases for Alzheimer’s disease and other neurodegenerative diseases. Winner of the “Innovations in biotherapies and bioproduction” call for projects, financed by the French government as part of France 2030.
